May 30, 2018 08:46 AM EDT
R&D
Pharma

J&J hus­tles Leg­end’s promis­ing BC­MA CAR-T in­to PhI/II tri­al, win­ning an FDA green light to be­gin re­cruit­ing pa­tients

John Carroll

Editor & Founder

Af­ter spend­ing $350 mil­lion in cash to lay its hands on rights to Nan­jing-based Leg­end Biotech’s promis­ing BC­MA CAR-T LCAR-B38M (JNJ-68284528), the phar­ma gi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

GSK makes an­oth­er ADC deal, this time with BioN­Tech's part­ner Du­al­i­ty­Bio

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

On heels of Mar­i­Tide da­ta, Dan­ish obe­si­ty biotech dis­clos­es €80M Se­ries A

A service from the Financial Times